ViroSENS

Services for the Development of Antiviral Agents

HIVHepatitis & FlavivirusesRespiratoryHerpesEnteric

ImQuest BioSciences provides expert virology services to help our clients rapidly identify therapeutic and prevention products with the potential to inhibit the replication of viruses using state-of-the-art and established in vitro, ex vivo and in vivo models. The ImQuest BioSciences' staff has decades of virology experience with quality, efficient and cost-effective product development services for antiviral therapeutic agents and product development.

Our virology services begins with basic drug discovery screening and testing programs and follows a well-defined antiviral developmental pathway, guided by documents such as the FDA Points to Consider in the Preclinical Development of Antiviral Drugs for the Treatment of HIV Infection. Our services are available for the evaluation of small molecules, natural products, immune modulators, biologics and therapeutic antibodies and provide necessary support from initial discovery, structure-activity relationship evaluation, lead identification and IND-directed preclinical development.

The virology services provided as part of the ImQuest ViroSENS platform include:

  • Determination of efficacy and toxicity in established and fresh human cells
  • Range of Action Assays, including:
    • Efficacy evaluation in a variety of phenotypically distinct human cell types
    • Efficacy evaluation against drug-resistant virus isolates
    • Cell-to-cell transmission evaluation
    • Efficacy evaluation in chronic and latent models of infection
    • Virucidal activity evaluation
    • Effect of serum and serum protein on antiviral activity
    • Effect of time of drug addition and viral multiplicity of infection
    • Efficacy against a range of infectious viruses
  • Mechanism of action evaluations using cell-based, molecular/biochemical and enzymatic assays
  • Combination therapy evaluation with other FDA-approved and experimental inhibitors
  • Drug resistant virus selection and characterization analysis

Additional supportive services as part of the ImQuestSUCCESS platform:

Visit our Resource Library for additional publications, abstracts, and white papers. Contact Us to learn more.

Human Immunodeficiency Viruses

  • Hundreds of clinical and laboratory HIV-1 strains representative of Group M and O
  • Drug-resistant and multi-drug resistant HIV-1 isolates
  • Clinical and laboratory HIV-2 strains
  • Cell-based, molecular and enzymatic mechanism of action assays
  • Resistance selection and characterization
  • Combination drug interaction analysis

To view our white papers on HIV antiviral drug development, click on the links below.

Hepatitis and Flaviviruses

  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Zika Virus
  • Chikungunya virus
  • Surrogate Hepatitis C virus - Bovine viral diarrhea virus (BVDV)
  • Dengue virus subtypes 1 through 4
  • Yellow fever virus

To view our white papers and posters on Hepatitis and Flavivirus antiviral drug development, click on the links below:

Respiratory Viruses

  • Influenza virus (A & B)-Numerous wild-type and drug-resistant strains
  • Human Parainfluenza viruses (PIV)
  • Respiratory Syncytial viruses (RSV)
  • Human Rhinoviruses
  • Measles virus
  • Human Adenoviruses

To view our white papers on influenza antiviral drug development, click on the links below.

Herpes Viruses

  • Herpes Simplex virus type 1 and 2 (HSV-1, HSV-2)
  • Human Cytomegalovirus (CMV)
  • Varicella Zoster virus (VZV)

Enteric Viruses

  • Enteroviruses
  • Echoviruses
  • Coxsackie viruses
  • Poliovirus
  • Rotavirus
ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides service to evaluate the potential efficacy of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory disease, including in vitro toxicology and product formulation services.